UroToday - The Global Online Community of Urologists
ƒ PDT³~ P„ sÿùþ¬ï ªòñ ÆÓ;Æ;–ñ“gà Mè47Ï Ò³³}S”°Ž± YòJ2„&üÿ{µ'°u €ƒ ø–Zh*@÷½ûÀ—þ yd ` ¸ 7 ïÌ}÷½÷¿¾,íÈ¥iV.š®é.ÛšÇNÙÚ`NpÝR; aNi,pOÐÀ… €†íc˜Öݾ¯·æQ@D ¦&c£ÜWJ() ÙMßF è9m_—¶ ³W]sâ $û N´á žVþïÃÍUµm´²ŠÑ 8 I©* n±âŒDa ËÔf áÁ[ AU‘R P»SÞ΄ Éks |} Üj§‹Ù»£k“íÎ$Û ...
UroToday - The Global Online Community of Urologists
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
SUO 2024 Videos - urotoday.com
UroToday's exclusive Video Lecture coverage of SUO 2024.
Upcoming Events for Urologists and Oncologists - UroToday
ESMO Asia is an annual congress specifically focused on multidisciplinary oncology in the Asian region. It provides a platform for participants to share and discuss the latest research findings, clinical trials, and treatment strategies in the field.
About UroToday
About UroToday-GU Oncology Today ® UroToday - GU Oncology Today brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.This site presents content on critical areas of research and clinical practice, providing researchers and clinicians the opportunity to evaluate …
UroToday Video Channels
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
GU Onc Daily - UroToday
2024年8月27日 · World Congress of Endourology and Uro-Technology (WCET) 2024: Leave No Stone Unmeasured - Predicting Outcomes, and Innovations in Ureteroscopy Sent on 21 August 2024 Receive via e-mail
Clinical Trials in Urology - UroToday
2024年12月2日 · Cabozantinib, an oral tyrosine kinase inhibitor against MET and vascular endothelial growth factor receptor 2 (VEGFR2), is an agent that has had success in multiple tumor types, such as renal cell, hepatocellular and medullary thyroid cancer. There have been multiple randomized phase 3 trial ...
ESMO 2024 Quick Take Insights: A Focus on SPLASH - urotoday.com
2024年10月17日 · ESMO 2024, metastatic castration resistant prostate cancer (mCRPC), SPLASH trial,177Lu-PSMA-617, PSMAfore trial, 177Lu-PNT2002, enzalutamide, abiraterone, VISION trial, androgen receptor pathway inhibitor (ARPI).
ASCO GU 2024 Videos - UroToday
UroToday's exclusive Video Lecture coverage of ASCO GU 2024. Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with Metastatic Hormone-Sensitive Prostate Cancer - Alicia Morgans